Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

VIP (vasoactive intestinal peptide): does it work, is it legal, and what does it cost?

Natural nerve signaling peptide; small trials in lung artery hypertension and COVID-19 breathing failure showed no benefit; not FDA approved; FDA Category 1.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about VIP (vasoactive intestinal peptide)
Does it work in people?Evidence: Human RCT evidence

At least one randomized human trial in PubMed. See the evidence

Is it legal?Regulatory: In FDA review (Category 1)

Not FDA approved. Pharmacies compound it under FDA's interim policy, where state boards permit, while FDA evaluates its nomination. [5] [12] See legal status

What does it cost?Roughly 150 to 400 USD per month for compounded intranasal VIP through a prescribing clinic, plus consultation fees.
Side effects?Hypotension and flushing (vasodilation), the main dose limiting effect of intravenous use. Diarrhea (VIP is the cause of secretory diarrhea in VIPoma). Tachycardia. See side effects and interactions
Tested athlete?WADA: WADA status unclear

What is VIP (vasoactive intestinal peptide)?

VIP (vasoactive intestinal peptide) is a 28 amino acid neuropeptide, a signaling peptide made by nerve cells, that relaxes smooth muscle, widens blood vessels, and dampens inflammation. Its synthetic form, aviptadil, has been tested in small pulmonary hypertension (high blood pressure in the lung arteries) studies and in two randomized COVID-19 respiratory failure trials, the largest of which (TESICO, 461 patients in the aviptadil comparison) found no improvement in recovery. It is not FDA approved for any indication; it sits in FDA 503A Category 1 (nominated compounding ingredients still under evaluation), which means compounding is currently tolerated while FDA decides, and it is sold as a compounded nasal spray for chronic inflammatory conditions without trial evidence.

VIP (vasoactive intestinal peptide) is an endogenous 28 amino acid neuropeptide of the secretin/glucagon family. It is also known as Vasoactive intestinal polypeptide, Aviptadil, VIP nasal spray, RLF-100, Zyesami.

How does it work?

VIP binds the G protein coupled receptors VPAC1 and VPAC2, raising intracellular cyclic AMP. This relaxes vascular, airway, and gut smooth muscle, stimulates surfactant production by type II alveolar cells, and shifts macrophages and T cells toward anti inflammatory profiles by lowering TNF alpha, IL-6, and IL-12. It is degraded within minutes in plasma, which is why inhaled, intranasal, and continuous intravenous forms are used.

Key facts
ClusterImmune and antimicrobial
RoutesInhaled aerosol (pulmonary hypertension studies); Intravenous infusion (COVID-19 trials, hospital only); Intranasal spray (compounded, no trial evidence); Intracavernosal injection combined with phentolamine (approved in some European countries for erectile dysfunction)
Conditions studiedInflammation and inflammatory bowel disease
Recordv2, reviewed, verified Sep 29, 2026

What does the evidence say about VIP (vasoactive intestinal peptide)?

Evidence: Human RCT evidenceGrade assigned per the methodology.

Small human studies exist, and the randomized ones are negative or inconclusive. Petkov 2003 reported hemodynamic improvement in 8 patients with primary pulmonary hypertension after inhaled VIP, but Leuchte 2008 found only modest acute effects and limited chronic benefit in 20 patients. In COVID-19 respiratory failure, a 196 patient 60 day RCT (Youssef 2022) did not meet its primary endpoint, and the NIH sponsored TESICO trial (Brown 2023) found no benefit of intravenous aviptadil on recovery. No randomized trial supports the intranasal VIP used for chronic inflammatory response syndrome or mold illness.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials2657
Human observational studies228
Animal studies0n/a
All indexed studies4685

Human evidence

Petkov 2003: 8 patients with primary pulmonary hypertension, inhaled VIP 200 ug daily, open label, reduced pulmonary artery pressure and improved 6 minute walk over 3 months. Leuchte 2008: 20 patients with pulmonary hypertension of various causes, single inhalation produced a small acute fall in pulmonary vascular resistance; chronic treatment in 9 patients produced modest changes. Youssef 2022: 196 patients with critical COVID-19 respiratory failure randomized to intravenous aviptadil or placebo; the primary endpoint (alive and free of respiratory failure at day 60) was not significantly different. Brown 2023 (TESICO): 461 patients randomized to aviptadil versus placebo within the ACTIV-3b platform; aviptadil did not improve recovery and the trial stopped for futility.

Animal evidence

In rodent and sheep models VIP reduces lung injury from endotoxin and hydrochloric acid, lowers pulmonary artery pressure, and protects against sepsis. VIP knockout mice develop pulmonary hypertension and airway inflammation. VIP also reduces disease severity in mouse models of colitis, rheumatoid arthritis, and experimental autoimmune encephalomyelitis, which underlies its immunology interest.

Key studies

Indexed studies of VIP (vasoactive intestinal peptide)
StudyDesign and populationOutcomeGrade
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension2003 PMID 12727925Open label pilot study, 3 monthsn = 8 Adults with primary pulmonary hypertensionInhaled VIP reduced mean pulmonary artery pressure and pulmonary vascular resistance and improved 6 minute walk distance; no control groupEvidence: Human observational evidence
Inhalation of vasoactive intestinal peptide in pulmonary hypertension2008 PMID 18978135Acute hemodynamic study with a chronic open label extensionn = 20 Adults with pulmonary hypertension of various etiologiesSingle inhalation produced a small acute fall in pulmonary vascular resistance; 3 months of inhaled VIP in 9 patients produced modest hemodynamic changesEvidence: Human observational evidence
The use of IV vasoactive intestinal peptide (aviptadil) in patients with critical COVID-19 respiratory failure: results of a 60-day randomized controlled trial2022 PMID 36044317Randomized, double blind, placebo controlled trial, 60 daysn = 196 Adults with critical COVID-19 and respiratory failurePrimary endpoint (alive and free of respiratory failure at day 60) not significantly different from placeboEvidence: Human RCT evidence
Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial2023 PMID 37348524Randomized, double blind, placebo controlled platform trial (ACTIV-3b)n = 461 Adults hospitalized with COVID-19 acute hypoxemic respiratory failureAviptadil did not improve recovery versus placebo; enrollment stopped for futilityEvidence: Human RCT evidence

Conditions studied

Conditions with evidence for VIP (vasoactive intestinal peptide)
ConditionGradeNote
Inflammation and inflammatory bowel diseaseEvidence: Human observational evidenceUncontrolled human studies of inhaled VIP in sarcoidosis. The record's human_rct grade comes from intravenous aviptadil trials in COVID-19 respiratory failure, a different route and indication; not approved.

Is VIP (vasoactive intestinal peptide) legal in the United States?

Regulatory: In FDA review (Category 1)WADA: WADA status unclear

FDA and compounding status

Not an FDA approved drug in the United States. An aviptadil and phentolamine combination is approved in some European countries for erectile dysfunction, and aviptadil was studied under FDA authorized COVID-19 trials but never authorized or approved. Vasoactive intestinal peptide appears on the FDA 503A bulk drug substances list as Category 1 (nominated and under evaluation), so under FDA's interim policy FDA does not intend to act against a state-licensed 503A pharmacy that compounds it on a prescription if the policy's conditions are met, until FDA decides by rule. That is not an approval. It has not been placed on the bulks list, was not part of the April 2026 Category 2 withdrawals, and was not among the peptides FDA presented to the committee in July 2026.

WADA status

WADA status unclear. The current prohibited list does not name this compound explicitly and its class status is not settled. Athletes should ask their anti-doping organization before use.

Regulatory timeline

No regulatory events recorded.

Full tracker for VIP (vasoactive intestinal peptide) or the category-wide tracker.

Email me when VIP (vasoactive intestinal peptide)'s status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of VIP (vasoactive intestinal peptide) used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Inhaled VIP about 200 ug per day in four divided inhalations for 3 months (Petkov 2003, primary pulmonary hypertension) or a single inhalation of 100 ug (Leuchte 2008). Intravenous aviptadil in COVID-19 trials was infused at escalating rates of 50, 100, and 150 pmol/kg/hour over 12 hours on three successive days (Youssef 2022). No dose for intranasal VIP in chronic inflammatory conditions has been established in a randomized trial.

Routes reported

Routes of administration reported for VIP (vasoactive intestinal peptide)
#Route
1Inhaled aerosol (pulmonary hypertension studies)
2Intravenous infusion (COVID-19 trials, hospital only)
3Intranasal spray (compounded, no trial evidence)
4Intracavernosal injection combined with phentolamine (approved in some European countries for erectile dysfunction)

What are the side effects and interactions of VIP (vasoactive intestinal peptide)?

Side effects

Side effects reported for VIP (vasoactive intestinal peptide)
#Reported side effect
1Hypotension and flushing (vasodilation), the main dose limiting effect of intravenous use
2Diarrhea (VIP is the cause of secretory diarrhea in VIPoma)
3Tachycardia
4Nasal irritation with intranasal use (anecdotal)
5Hyperglycemia reported in infusion studies

Interactions

Interactions reported for VIP (vasoactive intestinal peptide)
#Interaction
1Additive blood pressure lowering with antihypertensives, PDE5 inhibitors, and nitrates (theoretical, based on mechanism)
2No formal drug interaction studies published

Contraindications

Contraindications for VIP (vasoactive intestinal peptide)
#Contraindication
1Hypotension or hemodynamic instability outside a monitored setting
2Pregnancy and breastfeeding (no data)
3Uncontrolled diarrhea

How do people access VIP (vasoactive intestinal peptide) legally?

Typical cost: Roughly 150 to 400 USD per month for compounded intranasal VIP through a prescribing clinic, plus consultation fees. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.

Access options

  • Conditional

    Prescription from a licensed provider filled by a 503A compounding pharmacy as an intranasal spray, while VIP remains in FDA Category 1.

  • Not available

    Not available as an FDA approved product.

  • Not available

    Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. PeptideAgent has not found an FDA warning letter or review that names VIP. [9] [10] [11]

VIP (vasoactive intestinal peptide) is not FDA approved. It is a nominated bulk substance FDA has not finished evaluating, and pharmacies compound it under FDA's interim policy where state boards permit, without any FDA finding on its safety or quality. [5] [12]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [9] [13] [14] [15] [16] [17]

What that means for you

  • A pharmacy that compounds VIP (vasoactive intestinal peptide) relies on FDA's interim policy, which has conditions and which FDA can change, so it carries some regulatory risk. [12]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [17]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [18]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [19] [20]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [15]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, WADA status is unclear; ask your anti-doping organization before any use. [7]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [17]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [21] [22] [23]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [11] [23] [24]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [17] [25] [26] [27] [28] [29]

Before you accept a compounded product, check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [17]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [21]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [11]
  • Pharmacy: Is this made for me on a prescription written in my name? [24]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [11] [23]
  • Prescriber: What is the legal basis for a pharmacy to compound VIP (vasoactive intestinal peptide): is it on the 503A bulks list, or compounded under FDA's interim policy? [5] [12]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [11]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [18]

Frequently asked questions

Is VIP peptide legal and FDA approved?

It is not FDA approved. It is listed in FDA 503A Category 1, meaning it was nominated for the compounding bulks list (ingredients pharmacies may use to compound drugs for individual patients) and is still under evaluation, so under FDA's interim policy FDA does not intend to act against a state-licensed 503A pharmacy that compounds it on a prescription if the policy's conditions are met, until FDA decides by rule. That is not an approval. It was not among the peptides FDA moved off Category 2 in April 2026 and was not among the peptides FDA presented to the committee in July 2026. [5] [6]

Does VIP nasal spray work for CIRS or mold illness?

There is no randomized trial of intranasal VIP for chronic inflammatory response syndrome, mold illness, or any related diagnosis. The claim rests on VIP's anti inflammatory effects in animals and on uncontrolled case series. The only randomized human VIP trials are in pulmonary hypertension and COVID-19, and the COVID-19 trials were negative. [3] [4]

Did VIP (aviptadil) work for COVID-19?

No. A 196 patient randomized trial did not meet its primary endpoint of being alive and free of respiratory failure at 60 days, and the NIH sponsored TESICO trial of 461 patients found no improvement in recovery with intravenous aviptadil and was stopped for futility. FDA did not authorize it. [3] [4]

What are the side effects of VIP?

VIP is a vasodilator, so low blood pressure, flushing, and fast heart rate are the main effects and limited the intravenous dose in COVID-19 trials. It stimulates intestinal secretion, so diarrhea can occur. Intranasal use has no controlled safety data; nasal irritation is reported anecdotally. [2] [3]

How is VIP taken?

In pulmonary hypertension studies it was inhaled as an aerosol (about 200 ug per day in four divided doses). In COVID-19 trials it was a 12 hour intravenous infusion on three consecutive days in the ICU. Compounded products are nasal sprays. No dose for the nasal spray has been set by a randomized trial. [1] [3]

How much does VIP nasal spray cost?

Compounded intranasal VIP typically runs 150 to 400 USD per month through a prescribing clinic, before consultation fees. Research chemical vials are cheaper, but sold for human use they are unapproved drugs. Prices were checked on the last verified date and vary by pharmacy. [5] [8]

Is VIP banned by WADA?

Unclear. VIP is not named on the WADA Prohibited List. Because an aviptadil product is approved in some countries, it does not clearly fall under S0 (non-approved substances), but it is not covered by any explicit exemption either. Athletes should ask their anti-doping organization before use. [7]

VIP vs thymosin alpha-1 for immune modulation?

Neither has randomized evidence for the immune support uses they are marketed for. Thymosin alpha-1 has approved indications abroad and hepatitis B trials; VIP's randomized trials are in pulmonary hypertension and COVID-19 and did not show benefit in the COVID-19 setting. Both are compounded in the US under different regulatory footing, and neither is FDA approved. [4] [5]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Petkov V et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003PubMed 12727925, 2003
  2. [2]Leuchte HH et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 2008PubMed 18978135, 2008
  3. [3]Youssef JG et al. The use of IV vasoactive intestinal peptide (aviptadil) in patients with critical COVID-19 respiratory failure: results of a 60-day randomized controlled trial. Crit Care Med 2022PubMed 36044317, 2022
  4. [4]Brown SM et al. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO). Lancet Respir Med 2023PubMed 37348524, 2023
  5. [5]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  6. [6]FDA: 503A bulk drug substances category lists (PDF, updated 2026; vasoactive intestinal peptide listed in Category 1)FDA, 2026
  7. [7]WADA Prohibited ListWADA, 2026
  8. [8]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  9. [9]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
  10. [10]FDA warning letter 594743, April 1, 2020, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2020

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 29). VIP (vasoactive intestinal peptide): evidence, legality, and access. https://peptideagent.ai/peptides/vip
HTML link
<a href="https://peptideagent.ai/peptides/vip">VIP (vasoactive intestinal peptide): evidence, legality, and access</a>, PeptideAgent, updated September 29, 2026.